....if they would only come out with something promising with regards to funding, etc. This would move rather quickly to the upside. Its wound fairly tight.
I agree. I would love to sell for $18-$20 but we all know that may/may not happen so my point to yours was, why not average down here? Either way the downside risk here is more minimal to any upside potential but if that upside potential is never achieved, during that process one could sell and at least get their investment monies back by buying down here. Anything more than your original monies is icing on the cake....
..........I grabbed some down in the .15-.16 levels and finally got my average down to 100k shares @ .53. I was wayyy up there for awhile but am holding back on more ammo just in case I see good things happening before .53
For those that couldn't pull up the interview:
SMYRNA, Ga. – Scientists working on an Ebola vaccine in Smyrna have announced a major milestone.
Dr. Harriet Robinson and her staff at GeoVax Labs are celebrating the bio-tech equivalent of a first inning home run -- they've created cells that mimic Ebola.
They are non-infectious cells called VLPs -- virus-like particles they predict will spur antibodies to ward off the deadly disease.
"Virus-like particles are the best vaccines because they really mimic the virus and train the immune system to recognize the virus should you be infected," said Robinson.
Robinson is a veteran scientist who developed an HIV vaccine currently in human testing. Her excitement about these stringy little blobs is contagious.
The next step in the process is animal testing, which they hope will begin in March.
Testing will first begin in rodents, then primates. They hope to perform clinical trial with humans in 2016.
...why wait that long? If you're intelligent enough you would sell now, take your realized loss and buy back after 30 days.
Even if you can't deduct your realized losses here against any realized gains elsewhere you still can deduct up to $3000 a year ($1500 for single) loss against your ordinary income,. as long as you've held the asset for at least a year. So if you can't be happy here then at least be savvy.....
Yeah Mort I hear ya. I believe the thing with developing an Ebola vaccine financially probably won't bring a company much profit,....what if would bring however is a HUGE audience to what else that company has in their pipeline.
...actually there are other partnerships being formed for an Ebola vaccine as we wait Mercks deal doesn't mean we're out of anythin...: Read article below.
BARDA Awards $30M toward NewLink-Merck Ebola Vaccine Candidate
The U.S. Biomedical Advanced Research and Development Authority (BARDA) has awarded a $30 million contract to a NewLink Genetics subsidiary toward supporting manufacturing and development activities of the Ebola vaccine candidate rVSV-EBOV the company is co-developing with Merck & Co.
The grant—awarded to NewLink subsidiary BioProtection Systems—is intended to cover the cost of clinical development through a new 330-person Phase Ib study, the companies reported.
“The current funding provided by BARDA is key to the rapid development of this Ebola vaccine candidate,” Charles J. Link, Jr., M.D., NewLink’s founder, chairman, CEO, and CSO, said in a statement. “These funds will support multiple facets of the accelerated Ebola vaccine program including the expansion of critical vaccine supplies and larger clinical studies.”
BioProtection Systems has been advancing rVSV-EBOV under a license from its initial developer, the Public Health Agency of Canada (PHAC). Merck obtained exclusive rights to rVSV-EBOV from NewLink, in return for joining NewLink in researching, developing, manufacturing, and distributing the Ebola vaccine. The value of the collaboration was not disclosed.
rVSV-EBOV has begun trials in the U.S., at NIH’s Clinical Center, and the Walter Reed Army Institute of Research Clinical Trials Center, as well as in Switzerland and Africa. The Swiss trial for all 59 volunteer patients was interrupted and placed on a temporary hold, a week before its scheduled end, as “a measure of precaution” following complaints by four of the volunteers complained of joint pains in their hands and feet, the University of Geneva Hospital said Dec. 11. The hold does not affect the other trial sites, which have continued with lower doses of the vaccine.
Scientists from PHAC’s National Microbiology Laboratory created rVSV-EBOV, with a significant portion of development funding to date coming from the CBRN [Chemical, Biological, Radiological, and Nuclear] Research and Technology Initiative, a federal program led by Defence Research and Development Canada.
Pending the results of Phase I trials unde rway, the NIH has announced plans to initiate in early 2015 a large randomized, controlled Phase II/III study to evaluate the safety and efficacy of rVSV-EBOV as well as another investigational Ebola vaccine candidate, ChAd3-EBOV, for which a clinical study was launched in October in Mali.
rVSV-EBOV is one of at least two clinical programs that have been launched toward development of Ebola treatments in 2014. The other is the program for ChAd3-EBOV, which has been developed by the Vaccine Research Center (VRC) of NIOH’s National Institute of Allergy and Infectious Diseases (NIAID), and is being manufactured by GlaxoSmithKline (GSK) Biologicals.
A third clinical program is expected to launch next month. Johnson & Johnson (J&J) has said it plans to start trials in January for a prime-boost Ebola vaccine regimen that combines AdVac® technology from Crucell Holland, part of J&J’s Janssen Pharmaceutical Cos., and Bavarian Nordic’s MVA-BN® Filovirus vaccine candidate.
Bavarian Nordic has committed to making available 1 million doses of MVA-BN over the coming year—with J&J saying that included 250,000 doses to be released by May for clinical trials. The vaccine was discovered through collaborative research with the NIH—whose NIAID is joining the companies in a partnership J&J announced back in September
Here are my answers to those questions;
3. No, not that I'm aware.
5. I've appropriated some money for that.
6. IMO yes. Its the lowest I've seen.
7. There is no question 7.
.....I here ya but the question now is......When does end of year selling end?
What do we do when stock prices go down?
Has anything (that we know of), recently changed for this company that is negative?
Does this company still have any potential with their science going forward?
Do I have some money in my portfolio that I would like to spend on a risk/high reward stock?
If so, does the share price of this risk reflect a buying opportunity that I haven't seen before with it?
Once you answer these questions yourself....you'll know what to do...:)